Philip Braginsky is co-chair of the Intellectual Property Group. He is also co-chair of the Pharmaceutical and Biologics and China practices. He provides clients with value creation services through intellectual property counseling, litigation and patent and trademark procurement in the life sciences, tech
A friend and strategic business advisor to academic and business leaders, Philip has assisted in and been responsible for the creation and success of numerous technologies and business ventures. He has founded several technology companies, sits on the boards of various for-profit and not-for-profit ventures, and is actively engaged in formulating intellectual asset strategies for many public and private companies.
Philip has been appointed an expert on intellectual property for the United Nations Commission on International Trade Law (UNCITRAL), Working Group VI (Securities Interests).
Prior to joining Tarter Krinsky & Drogin, Philip was a Partner at Sills Cummis and Gross, Counsel at Scully Scott Murphy and Presser, and had previously established the intellectual property practice of a New York general practice firm.
Philip also founded and served as President/General Counsel of Flow Science, Inc., a technology transfer company, and co-founded and is presently a Director of the DD Venture Fund.
Phillip is Secretary of the Board of Directors of the Lymphatic Education and Research Network.
Phillip is Secretary of the Board of Directors of the Lymphatic Education and Research Network.
What I do when not practicing law
Spend time with my family, visit galleries, live music, reading and cooking.
I LOVE SUGAR is much more than a candy store. The high-end retailer takes the candy we all love and delivers a magical experience. State of the art design, including custom fixtures and attention to details, is what the experiential retailer believes makes shoppers often refer to I LOVE SUGAR as "the Apple store of candy". In a trade dress and trademark infringement case brought by their competitor, It’Sugar claimed that I LOVE SUGAR infringed their trademark and the overall look and feel of It’Sugar retail stores.
Tarter Krinsky & Drogin successfully defended I love Sugar, a locally owned high-end candy retailer based in Myrtle Beach, South Carolina in a trade dress infringement case brought by their competitor It’Sugar.
Tarter Krinsky & Drogin represented Hackermeter, a coding challenge website, in the negotiation and closing of an acquisition with Pinterest. The start-up was launched at Y Combinator’s Demo Day in August and matched developers with companies through code challenges.
On June 21, Intellectual Property co-chair Philip Braginsky and partner Jing Xia will speak at CPhI China, the leading pharmaceutical ingredients show in China and the wider Asia-Pacific region
Amy Goldsmith, Philip Braginsky and Aasheesh Shravah will present the Lawline Webinar “To Be or Not To Be: That is the Abstract Question, Naturally.”
Amy Goldsmith and Philip Braginsky, Co-Chairs of the Intellectual Property Practice, presented the Lawline webinar “3D Printing: The Newest Dimension in IP Protection.”
Amy Goldsmith and Philip Braginsky, Co-Chairs of the Intellectual Property Practice, presented the Lawline webinar “Patent Design Strategy and the new Hague Agreement for Designs.”
Tarter Krinsky & Drogin partnered with Università Bocconi to host a full-day program as part of its In-Company Training Program. The presentation, titled “Setting up Shop: Key Legal Issues for the Retail Industry” focused on the key legal challenges for retail clients entering the U.S. market.
Intellectual Property Group co-chair Philip Braginsky authored an article featured in Medical Device and Diagnostic Industry (MD+DI) titled, “Patent Considerations for Connected Medical Devices.” In the article, Phil discusses why developing new solutions, the Internet of Things (IoT) and Blockchain must be important components of a medtech company’s strategic planning.
The Food and Drug Administration (FDA) recently enhanced its Paragraph IV (PIV) Certifications List with additional data fields. The PIV Certification List regularly publishes information regarding the 180-day exclusivity provided under 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act).
Historically, the information has included the name of the drug product, dosage form, strengths, RLD/NDA numbers and the date of first filing. The new data fields added by FDA will further help generic drug companies plan product development more strategically and are intended to increase approvals of more generic drugs.
In an important decision for the personal care and ingredients industries, the U.S. Court of Appeals for the Federal Circuit recently vacated a district court decision that held patent claims invalid as being directed to non-patent eligible subject matter in Natural Alternatives Int'l v. Creative Compounds, LLC (Case No. 18-295).
As an addition to our ongoing series designed to help board members properly discharge their fiduciary duties in relation to company intellectual property, our next topic is the board’s obligations relating to executive qualification and officer oversight. It has become well established that in the United States, intellectual property and other forms of intangible assets make up a greater portion, than was the case a few years ago, of a business enterprise’s balance sheet. We do not anticipate this trend ending any time soon and as such, the need for intellectual property proficiency must be a priority for all governing bodies.
There are three types of Premarket Notification 510(k)s that may be submitted to the U.S. Food & Drug Administration (FDA): Under the recently finalized Safety and
This past December, the U.S. Food and Drug Administration (FDA) issued a biosimilar industry guidance on a variety of topics. Mostly overlooked was a Q&A regarding safety protections in a 351(k) application. The FDA Commissioner thought the matter was important enough to single out in his comments released the same day, calling it a "critical issue."
As we start a new year, we would like to share with you some of our most popular legal alerts from 2018. Our top-read alerts range from construction, corporate and securities, labor and employment, tax and intellectual property, reflecting the broad array of our full-service practice. We hope that our alerts have been valuable to you and your colleagues, and demonstrate our commitment to providing helpful information to you.
The Sixth Annual Best Practices in IP Conference in Tel Aviv, which covered global best practices for issues affecting companies' IP, was another great success. Attendees benefited from top-notch educational opportunities and introductions to innovative companies.
Intellectual property can present operational risks - knowledge and protocols can help.
Although one might occasionally come across an article touching on intellectual property (IP) concerns in the corporate boardroom, not enough has been said on this topic. This is the first in a series of articles that are designed to help board members satisfy their duties of care regarding the various risks that IP often carries.
The U.S. Food and Drug Administration (FDA) recently finalized its publication on additive manufacturing (commonly referred to as 3-D printing) for medical devices.
According to FDA Commissioner Scott Gottlieb, the guidance is meant to "help manufacturers bring their innovations to market more efficiently by providing a transparent process for future submissions and making sure our regulatory approach is properly tailored to the unique opportunities and challenges posed by this promising new technology."
The U.S. Food and Drug Administration (FDA) recently updated the Orange Book to include patent submission dates. A patent submission date is the date the FDA receives patent information from the NDA holder. For each patent that claims a drug substance (active ingredient), drug product (formulation and composition), or method of use, the FDA requires all NDA applicants to submit the detailed patent information provided for under on 21CFR314.53. Now, the dates of these submissions are being recorded and published by the FDA.
The European Patent Office recently revised its Examination Guidelines. These Guidelines are primarily directed to the patent examiners and formalities officers of the EPO, but they are also helpful to anyone practicing before the EPO. This year the update contains a few important changes.
The U.S. Food and Drug Administration (FDA) recently published a draft guidance summarizing the differences between abbreviated new drug applications (ANDA) and 505(b)(2) applications. Both sections were added to the FD&C Act to provide new routes for obtaining approvals for drug applications. The guidance focuses on ANDA submissions under Section 505(j) of the FD&C Act, petitioned ANDAs under Section 505(j)(2)(C), and NDAs pursuant to Section 505(b)(2) and discusses the regulatory and scientific considerations for determining whether to file an ANDA or 505(b)(2) application.
Generally, a patent owner's rights are exhausted after an authorized sale; the patent owner cannot sue a downstream customer who purchased an authorized patented product from a third party reseller. So how can a patent owner control the resale of a patented product?
The U.S. Supreme Court recently held in a recent decision in Life Technologies Corp v. Promega Corp. that the "supply of a single component of a multicomponent invention for manufacture abroad does not give rise to § 271(f)(1) liability."
In the recent decision Trading Technologies International, Inc., v. CQG, Inc. et al., the Federal Circuit affirmed a district court's ruling that a software patent on a graphical user interface was patentable subject matter, and not directed to an abstract idea under Alice.
In December 2016, the FDA published an industry guidance related to the Biologics Price Competition and Innovation Act. This guidance offers suggestions to sponsors on the design and use of clinical pharmacology studies to support a claim of biosimilarity to a reference product.
Branded companies make millions of dollars each day that a generic version of a drug is held from the market.
On June 23rd, the UK voted to leave the European Union (Brexit).
Design patents continue to grow in importance for many industries. If your company designs tangible products or packages, there is a new, efficient way to seek international protection for design features.
With the goal of fostering public commentary, the new domain name .SUCKS was approved by ICANN. Despite objections from some in the IP community, the sunrise period for .SUCKS is now open; it runs until May 29th.
The patent landscape has changed regarding business method patents.
In the summer of 2014, the Supreme Court issued a decision in Alice Corp. v. CLS Bank which invalidated certain business method patents related to finance. The basis for the invalidation was that the patents covered an abstract idea not eligible for patent protection.
Many agreements include an indemnification clause typically using language like this: “Party A will defend, indemnify and hold harmless all claims, losses and damages against Party B related to its use of the Technology.”
In Non-Disclosure Agreements, there is often boilerplate language that includes trade secrets in the definition of “Confidential Information.” This seemingly innocuous language can lead to problems for the owner of the trade secrets.
Be wary of giving up your rights for "lost profits." In most jurisdictions, there are two types of "lost profits": (1) those arising from general damages (recovery of money that a party agreed to pay under a contract); and (2) those arising from consequential damages (recovery of money lost based on other business arrangements). The first is generally easier to prove, but often a party in breach can be reasonably expected to pay the second.
Clearly define the grant provisions of all of your IP contracts. If you want to transfer or receive "intellectual property" or "technology," ensure that these terms are well defined and unambiguous. Definitions matter! By making the contract terms clear, you can potentially reduce (or eliminate entirely) future litigation costs.